Nicoletti, F., Bruno, V., Ngomba, R. T , Gradini, R. and Battaglia, G. (2015) Metabotropic glutamate receptors as drug targets: what's new? Current Opinion in Pharmacology, 20 . pp. 89-94. ISSN 14714892
| Documents |
| ||||
![[img]](http://eprints.lincoln.ac.uk/style/images/fileicons/application_pdf.png) |
PDF
Metabototropic.pdf - Whole Document Restricted to Repository staff only 326kB |
| Item Type: | Article |
|---|---|
| Item Status: | Live Archive |
Abstract
The question in the title: 'what's new?' has two facets. First, are 'clinical' expectations met with success? Second, is the number of CNS disorders targeted by mGlu drugs still increasing? The answer to the first question is 'no', because development program with promising drugs in the treatment of schizophrenia, Parkinson's disease, and Fragile X syndrome have been discontinued. Nonetheless, we continue to be optimistic because there is still the concrete hope that some of these drugs are beneficial in targeted subpopulations of patients. The answer to the second question is 'yes', because mGlu ligands are promising targets for 'new' disorders such as type-1 spinocerebellar ataxia and absence epilepsy. In addition, the increasing availability of pharmacological tools may push mGlu7 and mGlu8 receptors into the clinical scenario. After almost 30 years from their discovery, mGlu receptors are still alive. © 2014 Elsevier Ltd.
| Keywords: | 2 amino 3 (3,4 dichlorobenzyloxy) 6 fluorobicyclo3.1.0hexane 2,6 dicarboxylic acid, 4 amino 2 thiabicyclo3.1.0hexane 4,6 dicarboxylic acid 2,2 dioxide, acetylcysteine, amantadine, atypical antipsychotic agent, azd 2066, basimglurant, dipraglurant, ketamine, levacecarnine, mavoglurant, metabotropic receptor, metabotropic receptor 2, metabotropic receptor 3, metabotropic receptor 4, metabotropic receptor 5, metabotropic receptor 7, metabotropic receptor 8, metabotropic receptor antagonist, n methyl dextro aspartic acid receptor, neuroleptic agent, parvalbumin, pomaglumetad methionil, ro 0711401, ro 4419513, ro 4432717, serotonin 2A receptor, unclassified drug, vu 0360172, ligand, metabotropic receptor, absence, antidepressant activity, Article, autism, cannabis addiction, central nervous system disease, cerebellum disease, cocaine dependence, depression, drug dependence, drug efficacy, drug targeting, drug tolerability, dyskinesia, fragile X syndrome, gene, GRM1 gene, GRM2 gene, happy puppet syndrome, human, long term depression, nonhuman, Parkinson disease, pathogenesis, phase 2 clinical trial (topic), protein expression, receptor down regulation, schizophrenia, thalamocortical tract, tobacco dependence, animal, Central Nervous System Diseases, drug design, drug effects, Epilepsy, Absence, metabolism, molecularly targeted therapy, pathophysiology, Spinocerebellar Ataxias, Animals, Humans, Ligands, Molecular Targeted Therapy, Receptors, Metabotropic Glutamate, Spinocerebellar Ataxias, NotOAChecked |
|---|---|
| Subjects: | B Subjects allied to Medicine > B210 Pharmacology |
| Divisions: | College of Science > School of Pharmacy |
| Related URLs: | |
| ID Code: | 22144 |
| Deposited On: | 04 Feb 2016 12:15 |
Repository Staff Only: item control page